# Neurodegeneration Therapeutic Hypotheses
## Hypothesis 1: TREM2 Agonism as Neuroprotective Strategy in Alzheimer's Disease
**Description:** Activation of TREM2 on microglia will enhance clearance of amyloid-beta plaques and reduce neurotoxic inflammation. TREM2 deficiency leads to reduced microglial clustering around plaques and increased neuronal damage, while agonist stimulation promotes a disease-suppressive microglial phenotype.
**Target:** TREM2 (Triggering Receptor Expressed on Myeloid Cells 2)
**Supporting Evidence:**
- TREM2 R47H variant significantly increases AD risk (hazard ratio ~3.5) (PMID: 24448038)
- TREM2 deficiency reduces microglial proliferation around plaques in 5xFAD mice (PMID: 29395067)
- TREM2 haploinsufficiency in humans causes Nasu-Hakola disease with presenile dementia (PMID: 21700621)
**Confidence:** 0.78
---
## Hypothesis 2: TFEB Activation to Restore Autophagy-Lysosomal Function in Parkinson's Disease
**Description:** Pharmacological activation of TFEB (Transcription Factor EB) will promote clearance of alpha-synuclein aggregates by enhancing lysosomal biogenesis. Impaired autophagy-lysosomal pathway is a central mechanism in synucleinopathy pathogenesis.
**Target:** TFEB (MITF/TFE family member)
**Supporting Evidence:**
- TFEB overexpression reduces alpha-synuclein aggregation in cellular models (PMID: 23392613)
- mTORC1 inhibition via rapamycin enhances TFEB nuclear translocation and autophagy (PMID: 21617036)
- Lysosomal storage defects (GBA mutations) increase alpha-synuclein aggregation (PMID: 18668040)
**Confidence:** 0.72
---
## Hypothesis 3: Nurr1 Agonism to Suppress Neuroinflammatory Cascade in Parkinsonian Disorders
**Description:** Nurr1 (Nuclear Receptor Related 1) agonists will transcriptionally suppress pro-inflammatory gene expression in microglia while maintaining dopaminergic neuron survival. Nurr1 is expressed in both dopaminergic neurons and surrounding glial cells.
**Target:** Nurr1 (NR4A2)
**Supporting Evidence:**
- Nurr1 knockdown causes progressive dopaminergic neuron loss in knock-in mice (PMID: 12084553)
- Nurr1 forms transrepression complexes with NF-κB to inhibit inflammatory mediators (PMID: 19808673)
- Nurr1 agonists reduce microglial activation and protect dopaminergic neurons (PMID: 25212984)
**Confidence:** 0.75
---
## Hypothesis 4: Inhibiting LRRK2 Kinase Activity to Reduce Synuclein Pathology
**Description:** Selective LRRK2 kinase inhibition will normalize impaired autophagy flux and reduce alpha-synuclein phosphorylation at Ser129, a post-translational modification that promotes aggregation. G2019S LRRK2 mutations (most common genetic cause of PD) cause hyperactive kinase signaling.
**Target:** LRRK2 (Leucine-Rich Repeat Kinase 2)
**Supporting Evidence:**
- LRRK2 G2019S mutation causes 2-3 fold increased kinase activity (PMID: 16856876)
- LRRK2 knockdown reduces alpha-synuclein-induced neurodegeneration in vivo (PMID: 25186242)
- LRRK2 inhibitors (PF-360, MLi-2) rescue lysosomal defects in mutant fibroblasts (PMID: 28661562)
**Confidence:** 0.80
---
## Hypothesis 5: Restoration of Glial NAD+ Metabolism as Broad Neuroprotective Approach
**Description:** Increasing NAD+ precursor supplementation (nicotinamide riboside or NMN) will activate SIRT1/PGC-1α signaling in astrocytes and microglia, restoring mitochondrial function, reducing oxidative stress, and suppressing neuroinflammation across multiple neurodegenerative conditions.
**Target:** SIRT1/NAD+ biosynthetic pathway
**Supporting Evidence:**
- NAD+ levels decline with aging and in neurodegeneration models (PMID: 20400966)
- NR supplementation extends lifespan and improves mitochondrial function in aged mice (PMID: 24077513)
- SIRT1 activation deacetylates and activates PGC-1α for mitochondrial biogenesis (PMID: 18171937)
**Confidence:** 0.68
---
## Hypothesis 6: C9orf72 Repeat Expansion Targeting with Antisense Oligonucleotides
**Description:** ASO-mediated degradation of expanded GGGGCC repeat transcripts will eliminate both toxic RNA foci and dipeptide repeat protein aggregates that cause FTD/ALS pathology. C9orf72 expansions are the most common genetic cause of both disorders.
**Target:** C9orf72 expanded repeat transcripts
**Supporting Evidence:**
- C9orf72 expansions are most common genetic cause of ALS and FTD (PMID: 21944779)
- ASO treatment reduces toxic RNA foci and DPR proteins in patient-derived neurons (PMID: 25374355)
- Phase 1/2 clinical trials demonstrate ASO safety and target engagement (NCT03601223)
**Confidence:** 0.85
---
## Hypothesis 7: Modulating Cholesterol Metabolism to Reduce Aβ Production
**Description:** Inhibition of SREBP2-mediated cholesterol biosynthesis in neurons will reduce amyloid precursor protein (APP) processing by γ-secretase, decreasing Aβ40/Aβ42 production. Membrane cholesterol directly influences APP compartmentalization in lipid rafts.
**Target:** SREBP2 (Sterol Regulatory Element Binding Protein 2)
**Supporting Evidence:**
- Cholesterol-rich lipid rafts facilitate amyloidogenic APP processing (PMID: 10436096)
- HMG-CoA reductase inhibitors (statins) reduce Aβ production in vitro (PMID: 12556232)
- SREBP2 activation increases β-secretase (BACE1) expression (PMID: 23748564)
**Confidence:** 0.62
---
## Summary Table
| Hypothesis | Target | Confidence | Primary Mechanism |
|------------|--------|------------|-------------------|
| 1 | TREM2 | 0.78 | Microglial activation |
| 2 | TFEB | 0.72 | Autophagy-lysosomal |
| 3 | Nurr1 | 0.75 | Anti-inflammatory |
| 4 | LRRK2 | 0.80 | Kinase signaling |
| 5 | NAD+/SIRT1 | 0.68 | Metabolic restoration |
| 6 | C9orf72 | 0.85 | Repeat transcript toxicity |
| 7 | SREBP2 | 0.62 | Cholesterol/Aβ metabolism |